Possible side effects
Blood clots can develop in the veins of the lower extremities (symptoms include swelling, pain and redness in the legs), which can travel through the blood vessels into the lungs, causing chest pain and difficulty breathing. If you experience any of these symptoms, contact your doctor immediately.
Like all medicines, Triftazine can cause side effects, although not everyone gets them.
Stop taking Triftazine immediately and call your doctor if you develop symptoms of an allergic reaction. These symptoms include a rash, trouble swallowing or breathing, and swelling of the lips, face, throat, or tongue.
If any of the following side effects occur after taking this medicine, call your doctor immediately:
- Rarely, patients may develop neuroleptic malignant syndrome, which results in fever, muscle stiffness, drowsiness, temporary loss of consciousness and requires emergency hospitalization for treatment.
- If you have chest pain (angina) and it gradually gets worse.
- If you suffer from a sore throat, high fever, feel very tired, turn pale, have bruises and nosebleeds. This may indicate that you have blood problems resulting from taking Triftazin.
- Very rarely, drugs such as Triftazin can cause involuntary muscle contractions. Symptoms that may occur include slurred speech, strange movements of the face, especially the tongue, eyes, head, or neck (for example, a twisting of the neck that causes an unnatural position of the head, muscle rigidity, tremors or restlessness, and difficulty sitting). In some patients (especially those taking Triftazine in large doses) it can cause involuntary muscle contractions that can last for years. These patients may experience persistent chewing or tongue movements or other slight movements of the neck, head, or trunk. These patients also experienced uncontrolled movements of the arms and legs.
- Very rarely, patients may also experience fast or irregular heartbeat, constipation, difficulty or inability to urinate, or fever.
- Sometimes some patients complain that they feel lethargic, while others complain that they feel agitated.
- If you have angina and the pain gradually gets worse.
- There have been very rare reports of jaundice (yellowing of the skin and eyes), vision problems, pigmentation changes and blood problems.
- In older people with dementia, there is a small increase in the number of deaths in patients taking antipsychotics compared with patients not taking antipsychotics.
- Very rarely, at high doses of Triftazin, hyperprolactinemia may develop, accompanied by galactorrhea, amenorrhea or gynecomastia; may affect some hormone-dependent breast neoplasms. Phenothiazines may cause ECG changes such as QT prolongation and T wave changes; data were obtained on the development of ventricular arrhythmias (VF, VT (rare)), sudden death; heart attack and drug-induced torsade de pointes (Torsades de pointes).
Some patients may also experience weakness, drowsiness, dizziness, restlessness, insomnia, dry mouth, blurred vision or eye problems, muscle weakness, loss of appetite, weakness when standing, weight gain, fluid retention causing swelling or confusion.
If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
Reporting Adverse Events
If you notice any side effects, tell your doctor, pharmacist or pharmacist, including any side effects not listed in this leaflet. You can also report side effects by going to the website www.arpimed.com and filling out the appropriate form “Report a side effect or ineffectiveness of a drug” and to the Scientific Center for Expertise of Medicines and Medical Technologies named after. Academician E. Gabrielyan by going to the website www.pharm.am to the “Report a side effect of a drug” section and fill out the form “Card of reporting a side effect of a drug.” Scientific center hotline phone number: +37410200505; +37496220505 By reporting side effects, you help gather more information about the safety of this drug.
How to store Triftazin
- The drug should be stored out of the reach of children, protected from moisture and light at a temperature of 150C -250C.
- Shelf life – 3 years. Do not take Triftazin after the expiration date indicated on the drug package. When indicating the expiration date, we mean the last day of the specified month.
- If the tablets change color or show other signs of deterioration, do not take the drug.
- Medicines should not be disposed of in wastewater or sewer systems. Ask your pharmacist how to dispose of any medicine you no longer need. These measures are aimed at protecting the environment.
Package contents and additional information
Triftazin contains
One film-coated tablet contains:
active substance: trifluoperazine – 5 mg (trifluoperazine hydrochloride – 6 mg);
excipients: microcrystalline cellulose, lactose monohydrate, povidone, corn starch, magnesium stearate, sodium starch glycolate, purified talc, hypromellose, propylene glycol, titanium dioxide, blue dye (brilliant blue).
What Triftazin looks like and contents of the pack:
Blue film-coated tablets.
Description of packaging
Cardboard packaging containing 48 tablets (2 blisters of 24 tablets each) along with a leaflet.
Vacation conditions
Dispensed by prescription.
Triphtazin
From the nervous system: drowsiness, dizziness, insomnia (at the beginning of treatment), with prolonged use in high doses (0.5 -1.5 g / day) - akathisia, dystonic extrapyramidal reactions (spasms of the muscles of the face, neck and back, tic-like movements or jerking, twisting movements of the body, inability to move the eyes, weakness in the arms and legs), parkinsonism (difficulty speaking and swallowing, loss of balance control, mask-like face, shuffling gait, stiffness in the arms and legs, tremors of the hands and fingers), tardive dyskinesia (smacking and puckering of lips, puffing out of cheeks, rapid or worm-like movements of the tongue, uncontrolled chewing movements, uncontrolled movements of arms and legs), neuroleptic malignant syndrome (seizures, difficulty or rapid breathing, rapid or irregular pulse, hyperthermia, unstable blood pressure, increased sweating, loss of urinary control, severe muscle rigidity, unusually pale skin, excessive fatigue and weakness), phenomena of mental indifference, delayed reaction to external irritations and other mental changes, convulsions.
From the genitourinary system: urinary retention, decreased potency, frigidity (at the beginning of treatment), decreased libido, ejaculation disorders, priapism, oliguria.
From the endocrine system: hypo- or hyperglycemia, hyperprolactinemia, galactorrhea, swelling or pain in the mammary glands, gynecomastia, amenorrhea, dysmenorrhea, weight gain.
From the digestive system: loss of appetite, dry mouth, constipation (at the beginning of treatment), bulimia or anorexia, nausea, vomiting, diarrhea, gastralgia, cholestatic jaundice, hepatitis, intestinal paresis.
From the senses: visual impairment - accommodation paresis (at the beginning of treatment), retinopathy, clouding of the lens and cornea, blurred visual perception.
From the hematopoietic organs: inhibition of bone marrow hematopoiesis (thrombocytopenia, leukopenia, agranulocytosis (4-10 weeks of treatment), pancytopenia, eosinophilia), hemolytic anemia.
Laboratory indicators: false-positive tests for pregnancy and phenylketonuria.
From the cardiovascular system: tachycardia, decreased blood pressure (including orthostatic hypotension) especially in elderly patients and persons with alcoholism (at the beginning of treatment), heart rhythm disturbances, prolongation of the QT interval, decrease or inversion of the T wave, increased frequency of attacks of angina pectoris (against the background of increased physical activity).
Allergic reactions: skin rash, urticaria, exfoliative dermatitis, angioedema.
Other: skin coloring from blue-violet to brown, photosensitivity, discoloration of the sclera and cornea, decreased tolerance to high temperatures (up to the development of heat stroke - hot dry skin, loss of the ability to sweat, confusion), myasthenia gravis.
Triftazin, 2 mg/ml, solution for intramuscular administration, 1 ml, 10 pcs.
Disorders of the blood and lymphatic system: inhibition of bone marrow hematopoiesis (thrombocytopenia, leukopenia, agranulocytosis (4-10 weeks of treatment), pancytopenia, eosinophilia), hemolytic anemia.
Immune system disorders: skin rash, urticaria, exfoliative dermatitis, angioedema, photosensitivity.
Endocrine system disorders: hypo- or hyperglycemia, glucosuria, hyperprolactinemia, galactorrhea.
Metabolic and nutritional disorders: weight gain.
Mental disorders: phenomena of mental indifference, delayed reaction to external stimuli and other mental changes, seizures, bulimia or anorexia.
Nervous system disorders: headache, drowsiness, dizziness, insomnia (at the beginning of treatment), with long-term use in high doses (0.5–1.5 g/day) - akathisia, dystonic extrapyramidal reactions (spasms of the muscles of the face, neck and back, tic-like movements or jerking, twisting movements of the body, inability to move the eyes, weakness in the arms and legs), parkinsonism (difficulty speaking and swallowing, loss of balance control, mask-like face, shuffling gait, stiffness of the arms and legs, trembling of the hands and fingers ), tardive dyskinesia (smacking and wrinkling of lips, puffing out of cheeks, rapid or worm-like movements of the tongue, uncontrolled chewing movements, uncontrolled movements of arms and legs), neuroleptic malignant syndrome (convulsions, difficulty or rapid breathing, hyperthermia, increased sweating, severe muscle rigidity, unusually pale skin, excessive fatigue and weakness), tremors.
Violations of the organ of vision: visual impairment - accommodation paresis (at the beginning of treatment), retinopathy, clouding of the lens and cornea, blurred visual perception, discoloration of the sclera and cornea.
Cardiac disorders: tachycardia, heart rhythm disturbances, rapid heartbeat or irregular pulse, changes in the electrocardiogram, prolongation of the Q-T interval, decrease or inversion of the T wave, increased frequency of angina attacks (against the background of increased physical activity), cardiac arrest.
Vascular disorders: unstable blood pressure, decreased blood pressure (including orthostatic hypotension), especially in elderly patients and persons with alcoholism (at the beginning of treatment).
Gastrointestinal disorders: loss of appetite, dry mouth, constipation (at the beginning of treatment), bulimia or anorexia, nausea, vomiting, diarrhea, gastralgia, intestinal paresis.
Disorders of the liver and biliary tract: cholestatic jaundice, hepatitis, hepatotoxicity.
Disorders of the skin and subcutaneous tissues: discoloration of the skin from blue-violet to brown, decreased tolerance to high temperatures (up to the development of heat stroke - hot dry skin, loss of the ability to sweat), myasthenia gravis.
Renal and urinary tract disorders: urinary retention, loss of urinary control, oliguria.
Disorders of the genital organs and mammary gland: swelling or pain in the mammary glands, gynecomastia, amenorrhea, dysmenorrhea, decreased libido, decreased potency, frigidity (at the beginning of treatment), ejaculation disorders, priapism.
Impact on the results of laboratory and instrumental studies: false-positive tests for pregnancy and phenylketonuria.
General disorders and disorders at the injection site: infiltrates may occur, and contact dermatitis may occur if liquid forms come into contact with the skin.
When taking phenothiazine antipsychotics, cases of sudden death (including those possibly caused by cardiac causes) have been reported.
